newsfilter
← Latest News
Business Wire·

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

Agreement supports the identification of patients eligible for Alzheimer's disease biomarker testing through Tempus Next and enables neurologists to order LucentAD® Complete on Tempus' clinical ordering